An international group of experts has successfully applied new therapy to the first seven COVID-19 patients. All patients treated with a specific type of stem cell survived. Successful treatment of these patients, with an international consortium of experts, was performed at Beijing YouAn Hospital, Capital Medical University, China, with the approval and protocols of the Chinese Center for Disease Control and Prevention and the National Health Commission of China.
Mesenchymal stem cell therapy belongs to the group of Advanced Cell Therapies. These therapies require sophisticated crafting technology. Resources are limited, so it certainly cannot be for widespread use and simpler forms. This therapy has a vital role to play for the survival of critically ill patients. These cell lines are produced by very few centres in the world, in Europe, Australia, India and Israel. From Europe there are centres in Germany, France and Turkey. There is also a Swiss company with facilities in Slovenia (MBSI – Educell), which specializes in the production of such cell therapies